A Randomized, Double-Blind, Placebo and Calibrator Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Doses of VAK694 in Subjects With Seasonal Rhinitis During Natural Exposure to Allergen.

Trial Profile

A Randomized, Double-Blind, Placebo and Calibrator Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Doses of VAK694 in Subjects With Seasonal Rhinitis During Natural Exposure to Allergen.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2012

At a glance

  • Drugs Fluticasone propionate; VAK 694
  • Indications Seasonal allergic rhinitis
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 24 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Apr 2012 Actual patient number is 35 as reported by ClinicalTrials.gov.
    • 01 Sep 2010 Planned end date changed from 1 Nov 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top